PharmaTimes4 小时
Amlenetug receives FDA Fast Track Designation
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
PharmaTimes4 小时
Bimekizumab shows long-term efficacy in hidradenitis suppurativa
After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.